S100B inhibition protects from chronic experimental autoimmune encephalomyelitis

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• S100B, an inflammatory molecule, is linked to demyelination in multiple sclerosis.
• S100B's role in multiple sclerosis pathology suggests therapeutic potential.
• Pentamidine is a small molecule that neutralizes S100B.

Purpose of the Study:

• To investigate the role of S100B in chronic experimental autoimmune encephalomyelitis (EAE).
• To evaluate pentamidine's therapeutic potential in blocking S100B in EAE.
• To explore pentamidine's mechanism of action in EAE.

Main Methods:

• Administration of pentamidine to EAE models.
• Assessment of clinical symptoms and recovery.
• Analysis of pathological outcomes including oligodendrogenesis, neuroinflammation, astrocyte reactivity, microglia phenotype, and regulatory T cell density.

Main Results:

• Pentamidine treatment prevented severe clinical symptoms and improved recovery in chronic EAE.
• S100B blockade by pentamidine protected against impaired oligodendrogenesis and reduced neuroinflammation.
• Pentamidine reduced astrocyte reactivity and pro-inflammatory microglia, and increased regulatory T cells.

Conclusions:

• S100B is a key driver of neuroinflammation in EAE.
• Pentamidine demonstrates an uncharacterized mode of action.
• Pentamidine shows promise as an anti-inflammatory and remyelinating therapy for progressive multiple sclerosis.